Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

被引:6
作者
Onishi, Sachiyo [1 ]
Tajika, Masahiro [1 ]
Tanaka, Tsutomu [1 ]
Yamada, Keisaku [1 ]
Kamiya, Tomoyasu [1 ]
Abe, Tetsuya [2 ]
Higaki, Eiji [2 ]
Fujieda, Hironori [2 ]
Nagao, Takuya [2 ]
Inaba, Yoshitaka [3 ]
Muro, Kei [4 ]
Shimizu, Masahito [5 ]
Niwa, Yasumasa [1 ]
机构
[1] Aichi Canc Ctr Hosp, Dept Endoscopy, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[2] Aichi Canc Ctr Hosp, Dept Surg Gastroenterol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[3] Aichi Canc Ctr Hosp, Dept Diagnost & Intervent Radiol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[4] Aichi Canc Ctr Hosp, Dept Clin Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[5] Gifu Univ, Grad Sch Med, Dept Gastroenterol Internal Med, 1-1 Yanagido, Gifu 5011194, Japan
关键词
esophageal squamous cell carcinoma; neoadjuvant chemotherapy; sarcopenia; SKELETAL-MUSCLE MASS; PULMONARY COMPLICATIONS; PSOAS MUSCLE; SARCOPENIA; CANCER; OUTCOMES; PREDICTOR; NUTRITION; MORTALITY; IMPACT;
D O I
10.3390/jcm11030508
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Effects of changes in body composition during neoadjuvant chemotherapy (NAC) on perioperative complications and prognosis are unknown in patients with esophageal squamous cell carcinoma (ESCC). A total of 175 patients who underwent surgery for ESCC in our hospital between 2016 and 2019 were examined. The psoas muscle index (PMI) was calculated from the total psoas muscle area, and the visceral fat mass (VFM) at the umbilical level was measured. We defined body composition change (BCC) group as those with increased VFM of >= 3% and decreased PMI of >= 3% during NAC. Sarcopenia (S) was defined as PMI < 5.89 (male) and <4.06 (female). Nutritional assessment using the Subjective Global Assessment tool was performed upon admission. The percentages of BCC group, pre-NAC S, and post-NAC S was 32.5%, 79.4%, and 80.0%, respectively. BCC group had significantly more postoperative complications (p < 0.01) and longer hospital stays (p = 0.03) than groups pre-NAC S and post-NAC S. Overall survival (OS) analysis using the Cox hazard model showed that stage III (p < 0.01) and post-NAC S (p = 0.03) were poor prognostic factors. Changes in body composition during NAC affected perioperative complications and prognosis of patients with ESCC.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] The MRI radiomics signature can predict the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma
    Lu, Shuang
    Wang, Chenglong
    Liu, Yun
    Chu, Funing
    Jia, Zhengyan
    Zhang, Hongkai
    Wang, Zhaoqi
    Lu, Yanan
    Wang, Shuting
    Yang, Guang
    Qu, Jinrong
    [J]. EUROPEAN RADIOLOGY, 2024, 34 (01) : 485 - 494
  • [42] An in-depth analysis on the effects of body composition in patients receiving neoadjuvant chemotherapy for urothelial cell carcinoma
    MacDonald, Landan
    Rendon, Ricardo A.
    Thana, Myuran
    Wood, Lori
    MacFarlane, Robyn
    Bell, David
    Duplisea, Jon
    Mason, Ross
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2024, 18 (06): : 180 - 184
  • [43] Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma
    Nakaya, Seiichi
    Ogawa, Ryo
    Hayakawa, Shunsuke
    Fujihata, Shiro
    Okubo, Tomotaka
    Sagawa, Hiroyuki
    Tanaka, Tatsuya
    Takahashi, Hiroki
    Matsuo, Yoichi
    Takiguchi, Shuji
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [44] Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma
    Lu, Hao
    Liu, Jun-Feng
    Rong, Yu
    Liu, Xin-Bo
    Wang, Yan
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 28 (06) : 867 - 869
  • [45] The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
    Lv, Huilai
    Huang, Chao
    Li, Jiachen
    Zhang, Fan
    Gai, Chunyue
    Liu, Zhao
    Xu, Shi
    Wang, Mingbo
    Li, Zhenhua
    Tian, Ziqiang
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [46] Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy
    Kong, Yue
    Su, Miaoyi
    Fang, Jun
    Chen, Mengyuan
    Zheng, Chao
    Jiang, Youhua
    Tao, Kaiyi
    Wang, Changchun
    Qiu, Guoqin
    Ji, Yongling
    Wang, Yuezhen
    Yang, Yang
    [J]. SCIENTIFIC REPORTS, 2024, 14 (01):
  • [47] Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma
    Yoko Hiraki
    Yutaka Kimura
    Motohiro Imano
    Hiroaki Kato
    Mitsuru Iwama
    Osamu Shiraishi
    Atsushi Yasuda
    Masayuki Shinkai
    Tomoki Makino
    Masaaki Motoori
    Makoto Yamasaki
    Hiroshi Miyata
    Takao Satou
    Taroh Satoh
    Hiroshi Furukawa
    Masahiko Yano
    Yuichiro Doki
    Takushi Yasuda
    [J]. Surgery Today, 2021, 51 : 118 - 126
  • [48] Prognostic significance of sarcopenia in patients undergoing esophagectomy for superficial esophageal squamous cell carcinoma
    Oguma, J.
    Ozawa, S.
    Kazuno, A.
    Yamamoto, M.
    Ninomiya, Y.
    Yatabe, K.
    [J]. DISEASES OF THE ESOPHAGUS, 2019, 32 (07)
  • [49] Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan
    Kaida, Hayato
    Kitajima, Kazuhiro
    Nakajo, Masatoyo
    Ishibashi, Mana
    Matsunaga, Tomoyuki
    Minamimoto, Ryogo
    Hirata, Kenji
    Nakatani, Koya
    Hung, Ao
    Hattori, Satoshi
    Yasuda, Takushi
    Ishii, Kazunari
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (11) : 3666 - 3682
  • [50] Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy
    Konishi, Hirotaka
    Fujiwara, Hitoshi
    Shiozaki, Atsushi
    Hiramoto, Hidekazu
    Kosuga, Toshiyuki
    Komatsu, Shuhei
    Ichikawa, Daisuke
    Okamoto, Kazuma
    Otsuji, Eigo
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (01) : 95 - 101